Introduction
HIV and tuberculosis (TB) are leading global causes of mortality and morbidity. 1 In 2000, 7-12% of the estimated 8.3 million new TB cases worldwide and 26% of new cases in the USA were attributed to HIV infection. 1 However, the incidence of TB in HIV patients remains high in areas where TB is prevalent. 2 The incidence of TB is highest among patients with advanced HIV disease. 3 Not only does HIV increase the risk of reactivating a latent Mycobacterium tuberculosis (MTB) infection, it also increases the risk of rapid TB progression soon after infection or re-infection with MTB. Highly active antiretroviral therapy (HAART) dramatically decreases the incidence of opportunistic infections and death in patients with advanced HIV infection, including those with TB. 1 The immune recovery associated with HAART results in dramatic clinical benefits, but this restoration of immunity may result in immunopathological reactions and clinical deterioration when HAART is initiated in patients with TB. 4 Some patients experience temporary exacerbation or worsening of symptoms, signs, and/or radiographic manifestations of TB disease. This phenomenon is termed 'immune reconstitution inflammatory syndrome' (IRIS). 4 In this paper, we summarize the incidence, clinical presentations, and potential mechanisms of these conditions and we describe therapeutic methods.
Methods
A literature search using the MEDLINE database for the period January 1990 through October 2007 was performed to identify all original studies on the immune reconstitution disease associated with MTB infection. A full-text search using the following MeSH terms 'antiretroviral immune reconstitution syndrome' or 'immune paradoxical reaction' or 'immune reconstitution inflammatory syndrome' or 'immune reconstitution syndrome' or 'paradoxical worsening' and 'Mycobacterium tuberculosis' or 'tuberculosis' was effected. A review of the bibliographies of relevant articles was also conducted. Abstracts of all identified articles were reviewed, and any relevant study, as determined on the basis of the abstract, was reviewed in full. We identified 51 articles for review on the basis of the criteria stated below. Studies were included if they were written in English, involved human subjects, and reported data associated with MTB infection. Many additional papers were identified from the references of other published papers. Any studies that did not clearly meet these criteria were reviewed by two investigators (SL and EN) who reached a consensus regarding inclusion or exclusion of the article. The investigators established inclusion and exclusion criteria before reviewing abstracts and articles. The reported cases of TBassociated IRIS in the reviewed literature are shown in Table 1 .
5-58
Finally, considering all reviewed articles with available data, the delta CD4 cell count and the delta viral load were calculated as the differences between the CD4 cell count and the HIV plasma viral loads (VL) at IRIS onset and at baseline. Linear correlations between both delta CD4 cell count and viral load and the time on anti-TB regimens and on HAART before IRIS onset were calculated. The level of significance was set at 0.05. All the analyses were performed using SPSS for Windows 13.0 (SPSS Inc., Chicago, IL, USA).
Before presenting the results of our review, some limitations need to be discussed. Most of the revised original manuscripts had a small population, were cases series or single case reports, and were retrospective; no the recent proposal of a case definition is still based on an experts' consensus only. 59 
Epidemiology
Studies performed in Europe and the USA reported an incidence of TB-associated IRIS varying between 11% and 45%. 7, 14, 16, 18, 22, 30, 41 Breton et al. retrospectively studied antiretroviral-naive HIV-1-infected patients who were treated subsequently for TB and HIV-1 infection and observed that 16 patients (43%) had an IRIS. 30 Fishman et al. showed a transient worsening on radiography in 14/ 31 (45%) AIDS patients receiving antiretroviral therapy (ART), and of these, seven patients (23%) showed a severe worsening.
14 Narita et al. conducted a prospective study on 116 patients affected by TB to determine the incidence of IRIS. It occurred in 36% (12/33) HIVpositive patients with active TB receiving HAART, compared to 7% of cases (2/28 patients) not receiving HAART and 2% of cases (1/55 patients) who were not HIV-infected. 7 In a retrospective study of a group of 33 HIV-infected patients with mycobacterial disease, Olalla et al. registered nine cases of IRIS (27%), eight with MTB and one with Mycobacterium avium complex (MAC). The annual incidence of paradoxical responses during the first two years of the study was 20%, growing to 50% in the third year. 22 In a study performed in India by Furrer and Malinverni, 11/144 HIV-infected TB individuals with a follow-up of 72 person-years developed IRIS within 6 months of initiating HAART (incidence of IRIS 15.2 cases per 100 patient-years). 12 Finally, in an another observational longitudinal study in India, Patel et al. observed a total of 11 patients affected by IRIS. 37 However, paradoxical worsening of TB after initiation of TB treatment has been reported in 2-23% of treated TB patients without HIV infection. 60 On this point, Breen et al. 33 showed that IRIS occurred in 5/50 (10%) HIV-negative patients. In this group, disseminated TB was present in 4/5 (80%) patients. The median time from starting TB treatment to IRIS was 87 days (range 23-157 days).
Pathogenesis
That IRIS is secondary to underlying immunological change is widely accepted. 61 Several studies indicate that CD4 T cell recovery is sustained for !3-4 years in individuals with advanced HIV-1 infection who receive HAART. 62, 63 A reduction in plasma VL of more than 90% occurs within the first 1-2 weeks of HAART, and associated increases in CD4 lymphocyte counts occur in two principal phases. 64 The initial rapid increase in the number of circulating CD4 lymphocytes can usually be detected within 1-2 weeks of starting treatment and extends over the first 2-3 months of treatment. This increase largely represents a redistribution of activated CD45+ R0+ memory cells previously sequestered in lymphoid tissue and a reduction in apoptotic cell death. 65, 66 A slower second phase of CD4 expansion occurs over subsequent months and it may continues for years. This second phase represents expansion of naive CD45+ RA+ cells as thymic function is restored and is largely responsible for the long-term sustained rise in CD4 lymphocyte count. The rapid changes in CD4 numbers and function would appear to have temporal correlation with TBassociated IRIS. These phenomena may provide the opportunity for relevant pathogen-specific cells to gain access to sites of infection and engage in the host inflammatory response to foreign antigen. 4 Bourgarit et al. conducted a prospective, multicenter study on 19 consecutively enrolled patients with HIV-TB co-infection and reported that an acute exacerbation of mycobacteria-specific Th1 response immediately after the HIV infection control by HAART causes IRIS; these findings were independent of the CD4 lymphocyte count, the VL, and the time of HAART initiation. 67 Such reactions do not require the presence of viable organisms because they can occur after successful TB treatment. Acid-fast bacilli identified in IRIS events are often not found to be viable. In certain TB-associated IRIS patients, rapid restoration of the cutaneous tuberculin reaction has been observed. 7 The immunopathogenic mechanisms causing IRIS seem to be determined by the pathogen. 68 polymorphisms in cytokine genes to determine whether the encoded cytokines affect the IRIS pathogenesis. The authors observed that TNFA-308*2 was slightly more common in patients with herpesvirus-associated IRIS (p = 0.042 relative to patients without IRIS) and it was not present in any patients who had experienced IRIS associated with mycobacterial infection (p = 0.035 relative to patients without IRIS and p = 0.015 relative to seronegative controls). IRIS associated with mycobacterial infection occurred only in individuals who were homozygous for TNFA-308*1 (100% carriage), and non-carriage of IL6-174*C was more common than in patients without IRIS (relative risk = 3.0; p = 0.014). 70 However, future studies are needed to elucidate these points in the pathogenesis of IRIS.
Risk factors
Several risk factors for TB-associated IRIS have been identified. First, considering the available data in the literature, we assessed the time interval between initiation of TB therapy and starting HAART. In a systematic review of 86 cases, Lawn et al. showed that the median duration of anti-TB treatment before the onset of IRIS was 8 weeks (interquartile range (IQR) 5.5-11.5 weeks; range 2-48 weeks), whereas the median duration of HAART was only 4 weeks (IQR 2-10 weeks; range 1-44 weeks). 4 Manosuthi et al., in a retrospective study, described 21 HIV-positive TB patients with onset of TB-associated IRIS 32 days after initiating HAART. Of these, 15 (71.4%) patients developed IRIS within the first 2 months of HAART. 43 In a report by Tansuphasawadikul et al., the occurrence of IRIS was associated with a shorter time between anti-TB treatment and ART (31 days versus 90 days; p < 0.05). 57 Navas et al. showed that the median time that elapsed between the initiation of anti-TB therapy and the initiation of HAART was 22 days for patients who developed IRIS compared to 110 days for patients without IRIS. All patients with paradoxical responses had initiated HAART within the first 2 months of anti-TB therapy, in contrast with only two of the 11 patients who did not have the reactions (100% versus 18%, respectively; p = 0.002). 18 However, in , respectively, and the VL at baseline and IRIS onset were 5.6 log 10 copies/ml (IQR 5.1-5.8; range 3-6.1) and 2.6 log 10 copies/ml (IQR 2.6-3.7; range 1.7-4.4), respectively. Considering all original articles with available data on the viroimmunological count of patients at the initiation of an anti-TB regimen and at IRIS onset, graphical scatter plots were designed. Linear correlations between time on anti-TB regimens and on HAART before IRIS onset and both delta CD4 cell count and delta VL were calculated. No significant correlations were seen between immunological and virological parameters and time of initiation of any drugs before IRIS onset (Figures 1 and 2 ). 
Case definition and diagnosis
IRIS is mainly a clinical diagnosis, particularly when IRIS develops shortly after the initiation of anti-TB treatment and HAART. Laboratory tests may not be useful for differentiating between TB IRIS and anti-TB treatment failure, and the differential diagnoses of TB-associated IRIS need to be evaluated. Particularly, clinicians should exclude the occurrence of serious side effects of HAART (e.g., drug fevers), TB infection not responding to treatment due to resistance or poor adherence to treatment, and other HIV-or non-HIV-related infections and tumors. 72 75 Similarly all other case definitions were wealthycountry oriented and needed a high technology capacity other than human resources. Conversely, the major requirement for a working case definition of IRIS is the real applicability in low-resource settings. The International Network for the Study of HIV-associated IRIS invited around 100 researchers from 16 countries to Kampala, Uganda, in November 2006, to provide consensus IRIS case definitions suitable for high-income and low-resource countries. 56 Meintjes et al. published the consensus-based case definitions for TB-associated IRIS in 2008. First, paradoxical TB-associated IRIS: a paradoxical reaction in patients who have recently started HAART already on a favorable TB treatment. Second, antiretroviralassociated TB: a new TB diagnosis fulfilling World Health Organization criteria with inflammatory presentation in patients who are already on HAART. Third, unmasking TB-associated IRIS: a new TB diagnosis with inflammatory presentation complicated and unmasked by paradoxical reaction in patients who are already on HAART. Meintjes et al. considered that the omission of virological, immunological, and radiological laboratory parameters would not substantially compromise case definitions for TBassociated IRIS and that they could be used by clinicians and researchers in a variety of settings to promote standardization and comparability of data. 59 
Clinical manifestations
The IRIS in patients with TB may have protean manifestations, most commonly fever, nodal enlargement, and worsening pulmonary infiltrates observed on a chest radiograph, with or without recurrent respiratory symptoms. Clinical data available in the specific literature are summarized in Table 1 . Localized lymphadenopathy was present in 95 (45.2%) cases (cervical n = 37; intra-thoracic n = 26; intra-abdominal n = 15; axillary n = 11; inguinal n = 3; diffuse n = 2; supraclavicular n = 1), followed by pulmonary involvement in 51 (24.3%) patients, and central nervous system manifestations, as meningitis or abscesses, in 10 (4.8%). Serositis was commonly described; in particular, pleural effusion, ascites, and pericardial effusion were reported in 11 (5.2%), 7 (3.3%), and 1 (0.5%) case, respectively. Cutaneous and subcutaneous involvement was reported in 6 (2.8%) and 11 (5.2%) patients, respectively. Overall, gastrointestinal involvement, including ileo-cecal perforation, and intra-abdominal abscesses and hepatitis were reported in 12 (5.7%) patients. Rare manifestations were acute renal failure, epididymo-orchitis, hypercalcemia, and ocular involvement. However, although some manifestations of TB-associated IRIS were life-threatening, only seven deaths were reported overall. As reported in Table 1 , the localization of the more common clinical manifestations of IRIS usually reflect the initial sites of the TB presentation before starting HAART. However, in a few reports, IRIS clinical manifestations are characterized by the involvement of anatomical sites not previously affected by TB. 6, 10, 15, 20, 24, 31, 50, 52 This finding suggests that such a paradoxical reaction is triggered by various combinations of different factors and not only by the presence of microorganisms.
Therapy
The management of IRIS has not been well studied, but mild-tomoderate reactions can be managed with reassurance and perhaps non-steroidal anti-inflammatory agents. The cases of life-threatening forms of TB-associated IRIS can be managed with corticosteroids or temporary discontinuation of ART. 76 The use of systemic corticosteroids has been most widely employed in TBassociated IRIS, perhaps because of the previously accepted role for immune modulation in some forms of TB. 7, 10 The method of delivery, dosing, or duration of therapy is not currently well established. Short-term prednisone administration, in doses of 0.5 mg/kg daily for 2-4 weeks, appears to be well tolerated and safe when given to individuals maintained on stable HAART regimens. 77 In a double-blind placebo-controlled randomized clinical trial (RCT), Meintjes et al. showed that prednisone (1.5 mg/kg/day for 2 weeks, followed by 0.75 mg/kg/day for 2 weeks) reduced the need for hospitalization and procedures, and resulted in symptom improvement without an excess of corticosteroid side effects or severe infections. 78 However, given that the inflammatory response is a marker for immune restoration, HAART should be continued in all cases where the inflammatory reaction does not immediately threaten mortality or result in significant morbidity. 79 Surgical intervention may occasionally be required for complications such as organ rupture or for drainage procedures. 4 Finally, to reduce the incidence of IRIS, it has been suggested that bacillary load should be sufficiently reduced prior to the start of HAART by respecting a lengthy enough interval between the start of anti-TB treatment and HAART. The finding that all patients who developed TB-associated IRIS received HAART within 2 months of starting anti-TB therapy suggests that it may be prudent to wait to begin specific anti-HIV therapy in these patients, if their clinical situation allows. 18 Recently, Schiffer and Sterling conducted a decision analysis in hypothetical cohorts of 1000 patients in which HAART was initiated during the first 2 months of TB therapy (early) or during months 2 through 6 of TB therapy (deferred) or was withheld until after TB therapy (no-HAART).
Outcomes assessed were 1-year mortality and the combined outcome of 1-year mortality, new AIDS-defining illness, severe IRIS, and severe drug toxicity. 80 More recently, Abdool Karim et al.
conducted a prospective, open-label RCT to determine optimal timing of HAART initiation in relation to TB treatment. Patients were randomized to the integrated TB/HIV treatment arm (HAART initiation during TB treatment) or the sequential treatment arm (HAART initiation upon TB treatment completion). At intent-totreat analysis, the mortality rates were significantly lower in the integrated treatment arm regardless of CD4 count; for participants with CD4 counts <201 cells/ml, the HR was 0.54 (p = 0.044), while for CD4 counts from 201 to 500 cells/ml, the HR was 0.08 (p = 0.023). 81 Some experts would base the decision of when to start HAART on the immunological status of the patient. To reduce the occurrence of IRIS in patients with a CD4 <100/ml, HAART should be started after !2 weeks of TB treatment. For persons with a CD4 cell count of 100-200/ml, some experts would delay HAART until the end of the 2-month intensive phase of anti-TB treatment.
In those with a sustained CD4 cell count >200/ml, HAART could be started during the anti-TB maintenance phase and for those with a CD4 cell count >350 cells/ml, after finishing anti-TB treatment. 82 
Conclusions
TB and HIV disease have been inextricably bound together from the early years of the HIV/AIDS epidemic. In high-income countries, the rate of new MTB and HIV infections has slowed, and the numbers of individuals living with HIV infection have increased. In contrast, in resource-limited countries, where high rates of MTB infection already exist, both the incidences and the prevalence of HIV/AIDS and TB have continued to increase dramatically. 83 In this population, IRIS can be a potential complication following the initiation of HAART. Among the few case-control studies on HIV and non-HIV-infected patients, the incidence of IRIS has been found to be 28-36% and 7-10%, respectively. 7, 33 Furthermore, other studies comparing the IRIS and non-IRIS group have demonstrated that extrapulmonary TB, a lower CD4 cell count at baseline, an increase in the CD4 cell percentage and in the ratio of CD4/CD8 cells 1 month after initiation of HAART, and a greater decrease in the VL after introduction of HAART are variables associated with IRIS occurrence. 18, 30, 41, 43 Nevertheless, our systematic review failed to find a linear correlation between the time on TB regimen and on HAART and the viro-immunological parameters (delta CD4 cell count and VL). Moreover, the role of the mycobacterial antigen load in the pathogenesis of IRIS is an interesting aspect and is worthy of further studies. 61 Diagnosis and timing of HAART initiation are controversial issues. Firstly, the criteria for a diagnosis of IRIS proposed by French et al., Shelburne et al., or Colebunders et al. are not useful in resource-poor settings because they require the determination of viro-immunological parameters, or of the response to mycobacterial antigens, or of radiological findings. 68, 72, 73 Recently, the International Network for the Study of HIV-associated IRIS developed case definitions for high-income and resource-limited settings that focused specifically on clinical manifestations of TBassociated IRIS only. 59 The use of this consensus-based standardized case definition will help to provide greater insight into the incidence, clinical manifestations, risk factors, and impact of TBassociated IRIS, ultimately leading to better prevention and management strategies. Nevertheless, the correct diagnosis of active TB before ART initiation is the priority goal in low-income countries, and international efforts are needed to strengthen both laboratory and clinical capacity in TB diagnosis and treatment.
New diagnostic tools such as transrenal DNA for the detection of small extracellular urinary DNA fragments and cheap immune specific technology for use in the field, among others, are strongly advocated in the next years to provide early, prompt identification of TB cases. 84, 85 Secondly, the most frequent interval between starting HAART and the occurrence of IRIS is 30-60 days, however delayed IRIS has been described. 50 Research is needed to determine the relative merits of delaying initiation of ART to permit full culture-based investigation for TB versus starting ART without delay if there is no initial evidence of TB. Finally, more recently, Rebe et al., in a prospective study in South Africa, observed that the rates of TB drug resistance appear to be higher among patients presenting with suspected TB-associated IRIS compared with background MDR prevalence. These findings suggest that TB drug resistance should be excluded in all TB-associated suspects and corticosteroids should be used with caution in patients with presumed TB-IRIS until this result is known. 86 In conclusion, prospective studies performed in countries with high prevalence of HIV/MTB co-infection are needed as future works: (1) to identify a real comprehensive definition of IRIS, (2) to identify underlying mechanisms independently related to IRIS occurrence, (3) to identify exacerbating risk factors, (4) to identify the optimum time of HAART in a few selected conditions, and (5) to build therapeutic strategies to successfully treat IRIS, if needed.
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